



BPR1J-097 hydrochloride (1327167-19-0(free base))

Chemical Properties

CAS No. :		
Formula:	C27H29ClN6O3S	
Molecular Weight:	553.07	
Appearance:	no data available	
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year	

Biological Description

Description	BPR1J-097, a new-type small molecule FLT-3 inhibitor(IC50=11±7 nM), is with great anti tumor activities in vivo.	
Targets(IC50)	FLT	
In vivo	In FLT3-driven AML murine xenograft models, BPR1J-097 inhibited FLT3/signal transducer and activator of transcription 5 phosphorylation and triggered apoptosis in FLT3-driven AML cells and pronounced dose-dependent tumour growth inhibition and regression.	
Kinase Assay	Cells are treated with THZ531 for 6 hours.After treatment cells are washed 2-fold with cold PBS and then lysed in the following lysis buffer: Hepes(50 mM, pH 7.4), NaCl (150 mM), 1% Nonidet P40 substitute, EDTA (5 mM), DTT (1 mM), and protease/phosphatase cocktails.Lysates are treated with bio-THZ1 or bio-TH531 for pulldown overnight at 4°C.	

Solubility Information		, Ó
Solubility	DMSO: 5.53 mg/mL (10 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)	19

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8081 mL	9.0404 mL	18.0809 mL
5 mM	0.3616 mL	1.8081 mL	3.6162 mL
10 mM	0.1808 mL	0.904 mL	1.8081 mL
50 mM	0.0362 mL	0.1808 mL	0.3616 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Lin WH, et al. BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML. Br J Cancer. 2012 Jan 31;106(3):475-81.

Inhibitor • Natural Compounds • Compound Libraries • Recombinant Proteins This product is for Research Use Only• Not for Human or Veterinary or Therapeutic Use Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481